440 related articles for article (PubMed ID: 11511020)
1. Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications.
Li YY; Feldman AM
Drugs; 2001; 61(9):1239-52. PubMed ID: 11511020
[TBL] [Abstract][Full Text] [Related]
2. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
[TBL] [Abstract][Full Text] [Related]
3. MMP inhibition modulates TNF-alpha transgenic mouse phenotype early in the development of heart failure.
Li YY; Kadokami T; Wang P; McTiernan CF; Feldman AM
Am J Physiol Heart Circ Physiol; 2002 Mar; 282(3):H983-9. PubMed ID: 11834496
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase inhibition and the prevention of heart failure.
Lee RT
Trends Cardiovasc Med; 2001 Jul; 11(5):202-5. PubMed ID: 11597832
[TBL] [Abstract][Full Text] [Related]
5. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
Li YY; McTiernan CF; Feldman AM
Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
[TBL] [Abstract][Full Text] [Related]
6. Myocardial remodelling and matrix metalloproteinases in heart failure: turmoil within the interstitium.
Wilson EM; Spinale FG
Ann Med; 2001 Dec; 33(9):623-34. PubMed ID: 11817657
[TBL] [Abstract][Full Text] [Related]
7. Myocardial matrix degradation and metalloproteinase activation in the failing heart: a potential therapeutic target.
Spinale FG; Coker ML; Bond BR; Zellner JL
Cardiovasc Res; 2000 May; 46(2):225-38. PubMed ID: 10773226
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases: pathways of induction by bioactive molecules.
Tsuruda T; Costello-Boerrigter LC; Burnett JC
Heart Fail Rev; 2004 Jan; 9(1):53-61. PubMed ID: 14739768
[TBL] [Abstract][Full Text] [Related]
9. Matrix metalloproteinases: regulation and dysregulation in the failing heart.
Spinale FG
Circ Res; 2002 Mar; 90(5):520-30. PubMed ID: 11909815
[TBL] [Abstract][Full Text] [Related]
10. Matrix Metalloproteinases in Myocardial Infarction and Heart Failure.
DeLeon-Pennell KY; Meschiari CA; Jung M; Lindsey ML
Prog Mol Biol Transl Sci; 2017; 147():75-100. PubMed ID: 28413032
[TBL] [Abstract][Full Text] [Related]
11. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
[TBL] [Abstract][Full Text] [Related]
12. [Involvement of matrix metalloproteinases in the regulation of myocardial extracellular matrix in patients with congestive heart failure].
Yang YJ; Zhang X; Zhu WL; Huang Y
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1693-6. PubMed ID: 16854324
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
[TBL] [Abstract][Full Text] [Related]
14. Selective matrix metalloproteinase inhibition with developing heart failure: effects on left ventricular function and structure.
King MK; Coker ML; Goldberg A; McElmurray JH; Gunasinghe HR; Mukherjee R; Zile MR; O'Neill TP; Spinale FG
Circ Res; 2003 Feb; 92(2):177-85. PubMed ID: 12574145
[TBL] [Abstract][Full Text] [Related]
15. Myocardial extracellular matrix remodeling in ischemic heart failure.
Gallagher GL; Jackson CJ; Hunyor SN
Front Biosci; 2007 Jan; 12():1410-9. PubMed ID: 17127391
[TBL] [Abstract][Full Text] [Related]
16. MMP inhibition and the development of cerebrovascular atherosclerosis: The road ahead.
Napoli C
Stroke; 2002 Dec; 33(12):2864-5. PubMed ID: 12494909
[No Abstract] [Full Text] [Related]
17. Inhibitor of lysyl oxidase improves cardiac function and the collagen/MMP profile in response to volume overload.
El Hajj EC; El Hajj MC; Ninh VK; Gardner JD
Am J Physiol Heart Circ Physiol; 2018 Sep; 315(3):H463-H473. PubMed ID: 29775412
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium.
Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K
J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705
[TBL] [Abstract][Full Text] [Related]
19. Matrix metalloproteinase inhibitors: a review on pharmacophore mapping and (Q)SARs results.
Kontogiorgis CA; Papaioannou P; Hadjipavlou-Litina DJ
Curr Med Chem; 2005; 12(3):339-55. PubMed ID: 15723623
[TBL] [Abstract][Full Text] [Related]
20. Alteration of matrix metalloproteinases in selective left ventricular adriamycin-induced cardiomyopathy in the pig.
Goetzenich A; Hatam N; Zernecke A; Weber C; Czarnotta T; Autschbach R; Christiansen S
J Heart Lung Transplant; 2009 Oct; 28(10):1087-93. PubMed ID: 19782292
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
